Aslani, Iris .

HRN: 24-25-40  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/13/2024
AMPICILLIN 500MG (VIAL)
05/13/2024
05/20/2024
IV
138
Q6
PCAP, T/C CNS INFECTION
Waiting Final Action 
05/13/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
05/13/2024
05/20/2024
IV
27.5
OD
Pcap , T/c CNSInfectin
Waiting Final Action 
05/13/2024
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
05/13/2024
05/20/2024
PO
1ml
QID
Oral Candidiasis
Waiting Final Action 
05/13/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/13/2024
05/20/2024
IV
40
Q12
PCAP, T/C CNS Infection
Waiting Final Action 
05/13/2024
MUPIROCIN 2%, 15G (TUBE)
05/13/2024
05/20/2024
TOPICAL
Pea Sized Amount
3x A Day
Skin Infection
Waiting Final Action 
05/14/2024
CEFTRIAXONE 1G (VIAL)
05/14/2024
05/21/2024
INTRAVENOUS
275 Mg IVTT
Every 12 Hours
Empiric
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: